Trial Profile

A Phase 1/2, Multicentre, Open-Label Study of Modi-1 in Patients With Breast, Head and Neck, Ovarian, or Renal Cancer

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 09 Oct 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Modi-1 (Primary) ; Pembrolizumab (Primary)
Indications Carcinoma; Fallopian tube cancer; Head and neck cancer; Hypopharyngeal cancer; Laryngeal cancer; Mouth neoplasm; Oropharyngeal cancer; Ovarian cancer; Peritoneal cancer; Pharyngeal neoplasms; Renal cell carcinoma; Squamous cell cancer; Triple negative breast cancer
Focus Adverse reactions; First in man; Pharmacodynamics
Acronyms ModiFY
Sponsors Scancell

Most Recent Events

17 Sep 2025 Planned number of patients changed from 144 to 168.
17 Sep 2025 Planned End Date changed from 30 Jun 2026 to 1 Jul 2027.
17 Sep 2025 Planned primary completion date changed from 4 Apr 2026 to 1 Jul 2026.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com